Allovir Inc reports results for the quarter ended in January - Earnings Summary

Kalaris Therapeutics

13/08/2024 02:02

* Allovir Inc  ALVR.OQ  reported a quarterly adjusted loss
of 5
cents​​ per share for the quarter ended in January, higher than
the same quarter last year, when the company reported EPS of -48
cents.  The mean expectation of three analysts for the quarter
was for a loss of 10 cents per share. Wall Street expected
results to range from -14 cents to -7 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Allovir Inc's reported EPS for the quarter was a loss of 5
cents​.
    * The company reported a quarterly loss of $6.08 million.
    * Allovir Inc shares had risen by 0.3% this quarter and
gained 6.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 16.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and 2 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "sell."

Wall Street's median 12-month price target for Allovir Inc is
$0.95 
This summary was machine generated from LSEG data August 13 at
01:02 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.10          -0.05          Beat
 Mar. 31 2024      -0.16          -0.26          Missed
 Dec. 31 2023      -0.43          -0.36          Beat
 Sep. 30 2023      -0.42          -0.39          Beat